Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Diaz

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
Neurology|June 26, 2020
Sex-driven modifiers of Alzheimer risk: A multimodality brain imaging studyAneela Rahman, Eva Schelbaum, Katherine Hoffman, et al.
JTO Clinical and Research Reports|October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLCSun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast CancerAditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
Stroke|March 18, 2020
Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic EventsSantosh B Murthy, Xian Wu, Ivan Diaz, et al.
British Journal of Cancer|November 24, 2020
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumoursMark T J van Bussel, Ahmad Awada, Maja J A de Jonge, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
Thorax|April 17, 2021
Attributable mortality of acute respiratory distress syndrome: a systematic review, meta-analysis and survival analysis using targeted minimum loss-based estimationLisa K Torres, Katherine L Hoffman, Clara Oromendia, et al.
Investigational New Drugs|December 22, 2015
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)Joanne W Chiu, Sebastien J Hotte, Christian K Kollmannsberger, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|December 11, 2021
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, et al.
Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.
Neurology|June 26, 2020
Sex-driven modifiers of Alzheimer risk: A multimodality brain imaging studyAneela Rahman, Eva Schelbaum, Katherine Hoffman, et al.
JTO Clinical and Research Reports|October 13, 2025
Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLCSun Min Lim, Ana Laura Ortega Granados, Gustavo Dix Junqueira Pinto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast CancerAditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
Stroke|March 18, 2020
Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic EventsSantosh B Murthy, Xian Wu, Ivan Diaz, et al.
British Journal of Cancer|November 24, 2020
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumoursMark T J van Bussel, Ahmad Awada, Maja J A de Jonge, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
Thorax|April 17, 2021
Attributable mortality of acute respiratory distress syndrome: a systematic review, meta-analysis and survival analysis using targeted minimum loss-based estimationLisa K Torres, Katherine L Hoffman, Clara Oromendia, et al.
Investigational New Drugs|December 22, 2015
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)Joanne W Chiu, Sebastien J Hotte, Christian K Kollmannsberger, et al.
Pageof 9